Related references
Note: Only part of the references are listed.A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
D. S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2014)
Splicing factor mutations and cancer
Kenichi Yoshida et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2014)
Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
CLINICAL CANCER RESEARCH (2013)
Hairy-Cell Leukemia Presenting As Lytic Bone Lesions
Madison Tanner Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
J. William Harbour et al.
NATURE GENETICS (2013)
SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Simon J. Furney et al.
CANCER DISCOVERY (2013)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The spliceosome as a target of novel antitumour drugs
Sophie Bonnal et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Chronic Lymphocytic Leukemia with SF3B1 Mutation
Victor Quesada et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing
Liying Fan et al.
ACS CHEMICAL BIOLOGY (2011)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Luca Malcovati et al.
BLOOD (2011)
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
Akira Yokoi et al.
FEBS JOURNAL (2011)
Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer
Daniela Hungermann et al.
JOURNAL OF PATHOLOGY (2011)
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
Markus Ringner et al.
PLOS ONE (2011)
Synthetic mRNA Splicing Modulator Compounds with in Vivo Antitumor Activity
Chandraiah Lagisetti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells
Brian J. Albert et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The emerging role of splicing factors in cancer
Ana Rita Grosso et al.
EMBO REPORTS (2008)
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Yoshihiko Kotake et al.
NATURE CHEMICAL BIOLOGY (2007)
Targeting the spliceosome
Brian Rymond
NATURE CHEMICAL BIOLOGY (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein
CL Will et al.
EMBO JOURNAL (2002)
A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site
CL Will et al.
EMBO JOURNAL (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
